Table 1. Characteristics of included RCTs.

	Total no.	Disease	Dose of ω-3 PUFA	Duration	Control
Purrello, et al.(2007) [16]	36	NAFLD	2g	6mon	AHA
Feng-Shang Zhu, et al.(2008) [17]	134	NAFLD	2g	6mon	Placebo
Qing Xie, et al.(2008) [18]	46	NAFLD	4–5g	6mon	Placebo
Sofi, et al.(2010) [15]	11	NAFLD	0.83g	12mon	Placebo
Byrne, et al.(2014) [19]	103	NAFLD	4g	15–18mon	Placebo
Stephen, et al.(2015) [21]	34	NASH	3g	12mon	Placebo
Lu-Hua Yang, et al.(2015) [20]	78	NASH	6.4g	6mon	Normal saline

NAFLD, non-alcoholic fatty liver disease; AHA, alpha hydrxy acid; NASH, non-alcoholic steatohepatitis